Table 3.
Incidence of upper and lower gastrointestinal acute GVHD in evaluable patients with and without IBD prior to allogeneic HCT (A) and in patients with controlled or uncontrolled IBD at the time of allogeneic HCT (B).
| Table 3A: Baseline IBD | ||||
|---|---|---|---|---|
| Variables | Total N (%) |
No N (%) |
Yes N (%) |
P Value |
| Acute GVHD Upper Intestinal Tract (Nausea/Vomiting) | ||||
| No | 125 (94.7) | 82 (96.5) | 43 (91.5) | |
| Yes | 7 (5.3) | 3 (3.5) | 4 (8.5) | 0.246 |
| Acute GVHD Lower Intestinal Tract (Stage 1–4) | ||||
| No | 117 (88.6) | 75 (88.2) | 42 (89.4) | |
| Yes | 15 (11.4) | 10 (11.8) | 5 (10.6) | 0.845 |
| Table 3B: IBD Status (Controlled or Not) | |||||
|---|---|---|---|---|---|
| Variables | Total N (%) |
IBD Controlled with Meds N* (%) |
IBD Not Controlled with Meds N* (%) |
No IBD N (%) |
P Value |
| Acute GVHD Upper Intestinal Tract (Nausea/Vomiting) | |||||
| No | 124 (94.7) | 29 (93.5) | 13 (86.7) | 82 (96.5) | |
| Yes | 7 (5.3) | 2 (6.5) | 2 (13.3) | 3 (3.5) | 0.220 |
| Acute GVHD Lower Intestinal Tract (Stage 1–4) | |||||
| No | 117 (89.3) | 27 (87.1) | 15 (100.0) | 75 (88.2) | |
| Yes | 14 (10.7) | 4 (12.9) | 0 (0.0) | 10 (11.8) | 0.405 |
*
One IBD patient was reported to have unknown status of control at the time of allogeneic HCT, and so was excluded from analyses